NO20082214L - 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer - Google Patents
1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorerInfo
- Publication number
- NO20082214L NO20082214L NO20082214A NO20082214A NO20082214L NO 20082214 L NO20082214 L NO 20082214L NO 20082214 A NO20082214 A NO 20082214A NO 20082214 A NO20082214 A NO 20082214A NO 20082214 L NO20082214 L NO 20082214L
- Authority
- NO
- Norway
- Prior art keywords
- thiomorpholinyl
- dioxo
- indolyl
- modulators
- methanone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05111479 | 2005-11-30 | ||
PCT/EP2006/068649 WO2007062997A1 (en) | 2005-11-30 | 2006-11-20 | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082214L true NO20082214L (no) | 2008-07-31 |
Family
ID=37715997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082214A NO20082214L (no) | 2005-11-30 | 2008-05-14 | 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer |
Country Status (17)
Country | Link |
---|---|
US (1) | US7538101B2 (pt) |
EP (1) | EP1968967B1 (pt) |
JP (1) | JP4879996B2 (pt) |
KR (1) | KR101047204B1 (pt) |
CN (1) | CN101316838B (pt) |
AR (1) | AR057197A1 (pt) |
AT (1) | ATE507222T1 (pt) |
AU (1) | AU2006319232B2 (pt) |
BR (1) | BRPI0619266A2 (pt) |
CA (1) | CA2630307A1 (pt) |
DE (1) | DE602006021626D1 (pt) |
ES (1) | ES2362929T3 (pt) |
NO (1) | NO20082214L (pt) |
RU (1) | RU2412182C2 (pt) |
TW (1) | TWI327144B (pt) |
WO (1) | WO2007062997A1 (pt) |
ZA (1) | ZA200804349B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006014022D1 (de) * | 2005-11-30 | 2010-06-10 | Hoffmann La Roche | 5-substituierte indol-2-carbonsäureamidderivate |
JP4879997B2 (ja) * | 2005-11-30 | 2012-02-22 | エフ.ホフマン−ラ ロシュ アーゲー | 1,5−置換インドール−2−イルアミド誘導体 |
CA2674237C (en) * | 2006-12-28 | 2015-11-24 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
JP2010534217A (ja) * | 2007-07-25 | 2010-11-04 | エフ.ホフマン−ラ ロシュ アーゲー | ベンゾフラン−及びベンゾ[b]チオフェン−2−カルボン酸アミド誘導体ならびにヒスタミン3受容体モジュレータとしてのその使用 |
CN101910131B (zh) | 2007-11-16 | 2014-04-23 | 里格尔药品股份有限公司 | 甲酰胺、磺酰胺和胺化合物及其使用方法 |
WO2009076631A1 (en) | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
JP5658138B2 (ja) | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
US8785435B2 (en) * | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
AU2012388383C1 (en) * | 2012-08-23 | 2016-03-17 | Suven Life Sciences Limited | Acrylamide compounds as Histamine H3 receptor ligands |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
US5246960A (en) | 1984-12-21 | 1993-09-21 | Hoffmann-La Roche Inc. | Oxetanones |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5338755A (en) * | 1990-07-31 | 1994-08-16 | Elf Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
EP0978512A1 (en) * | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications |
TR200100472T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler |
WO2000009122A1 (en) | 1998-08-14 | 2000-02-24 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
DK1169312T3 (da) | 1999-03-29 | 2005-01-31 | Hoffmann La Roche | Glucokinaseaktivatorer |
EP1373204B1 (en) * | 2001-03-09 | 2016-10-26 | Janssen Pharmaceuticals, Inc. | Heterocyclic compounds |
GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
JP2006512404A (ja) * | 2002-10-22 | 2006-04-13 | グラクソ グループ リミテッド | H3受容体リガンドとしてのアリールオキシアルキルアミン誘導体 |
BRPI0512335A (pt) * | 2004-06-21 | 2008-03-04 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização |
JP4879997B2 (ja) * | 2005-11-30 | 2012-02-22 | エフ.ホフマン−ラ ロシュ アーゲー | 1,5−置換インドール−2−イルアミド誘導体 |
-
2006
- 2006-11-20 DE DE602006021626T patent/DE602006021626D1/de active Active
- 2006-11-20 WO PCT/EP2006/068649 patent/WO2007062997A1/en active Application Filing
- 2006-11-20 AU AU2006319232A patent/AU2006319232B2/en not_active Ceased
- 2006-11-20 CA CA002630307A patent/CA2630307A1/en not_active Abandoned
- 2006-11-20 JP JP2008542714A patent/JP4879996B2/ja not_active Expired - Fee Related
- 2006-11-20 KR KR1020087015759A patent/KR101047204B1/ko not_active IP Right Cessation
- 2006-11-20 CN CN2006800448115A patent/CN101316838B/zh not_active Expired - Fee Related
- 2006-11-20 BR BRPI0619266-1A patent/BRPI0619266A2/pt not_active IP Right Cessation
- 2006-11-20 ES ES06830045T patent/ES2362929T3/es active Active
- 2006-11-20 EP EP06830045A patent/EP1968967B1/en not_active Not-in-force
- 2006-11-20 AT AT06830045T patent/ATE507222T1/de active
- 2006-11-20 RU RU2008126389/04A patent/RU2412182C2/ru not_active IP Right Cessation
- 2006-11-28 TW TW095143983A patent/TWI327144B/zh active
- 2006-11-28 AR ARP060105249A patent/AR057197A1/es not_active Application Discontinuation
- 2006-11-28 US US11/605,005 patent/US7538101B2/en not_active Expired - Fee Related
-
2008
- 2008-05-14 NO NO20082214A patent/NO20082214L/no not_active Application Discontinuation
- 2008-05-20 ZA ZA200804349A patent/ZA200804349B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2009517431A (ja) | 2009-04-30 |
CN101316838A (zh) | 2008-12-03 |
TW200804339A (en) | 2008-01-16 |
US7538101B2 (en) | 2009-05-26 |
KR20080076979A (ko) | 2008-08-20 |
AR057197A1 (es) | 2007-11-21 |
TWI327144B (en) | 2010-07-11 |
AU2006319232B2 (en) | 2012-09-13 |
BRPI0619266A2 (pt) | 2011-09-27 |
ATE507222T1 (de) | 2011-05-15 |
RU2008126389A (ru) | 2010-01-10 |
ZA200804349B (en) | 2009-04-29 |
JP4879996B2 (ja) | 2012-02-22 |
EP1968967B1 (en) | 2011-04-27 |
AU2006319232A1 (en) | 2007-06-07 |
EP1968967A1 (en) | 2008-09-17 |
DE602006021626D1 (de) | 2011-06-09 |
KR101047204B1 (ko) | 2011-07-06 |
WO2007062997A1 (en) | 2007-06-07 |
CN101316838B (zh) | 2013-01-30 |
ES2362929T3 (es) | 2011-07-15 |
CA2630307A1 (en) | 2007-06-07 |
US20070123526A1 (en) | 2007-05-31 |
RU2412182C2 (ru) | 2011-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
NO20082939L (no) | Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer | |
NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
NO20082214L (no) | 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer | |
NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
NO20075082L (no) | Pyridin-3-karboksamidderivater som CB1-inversagonister | |
DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
NO20070336L (no) | Indolderivater som histamin-reseptorantagonister | |
ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
NO20076479L (no) | Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer | |
NO20050007L (no) | 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander | |
WO2006100081A3 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
NO20065733L (no) | Naftalinderivater nyttige som histamin-3-reseptor ligander | |
NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
DK1926729T3 (da) | Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander | |
NO20080394L (no) | N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav | |
NO20076060L (no) | Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
ATE466854T1 (de) | 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren | |
NO20090282L (no) | Syklopropylaminderivater som histamin H3 reseptormodulatorer | |
WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
DE602006014022D1 (de) | 5-substituierte indol-2-carbonsäureamidderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |